Heartflow (NASDAQ:HTFL) CEO John C.M. Farquhar Sells 32,676 Shares of Stock

Key Points

• CEO John C.M. Farquhar sold 32,676 Heartflow shares at an average price of $45, generating $1.47 million. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan and reduced his direct ownership by 7.77% to 388,044 shares.
• Heartflow shares rose 2.8% to $46.80, near the company’s 52-week high, following quarterly results that beat EPS expectations and showed 47.7% year-over-year revenue growth to $64.08 million.
• Analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target of $43.43, while institutional investors including Alyeska Investment Group and UBS increased their holdings during the second quarter.

Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) CEO John C.M. Farquhar sold 32,676 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $45.00, for a total value of $1,470,420.00. Following the transaction, the chief executive officer directly owned 388,044 shares of the company's stock, valued at $17,461,980. This trade represents a 7.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John C.M. Farquhar also recently made the following trade(s):

• On Friday, August 14th, John C.M. Farquhar sold 15,560 shares of Heartflow stock. The stock was sold at an average price of $39.06, for a total value of $607,773.60.
• On Monday, August 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $28.31, for a total value of $638,730.22.
• On Friday, July 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $27.75, for a total transaction of $626,095.50.
• On Wednesday, June 24th, John C.M. Farquhar sold 38,900 shares of Heartflow stock. The shares were sold at an average price of $35.00, for a total transaction of $1,361,500.00.
• On Wednesday, June 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $28.50, for a total transaction of $643,017.00.

Heartflow Trading Up 2.8%

Shares of Heartflow stock traded up $1.27 during trading on Thursday, hitting $46.80. 1,989,666 shares of the stock were exchanged, compared to its average volume of 1,522,363. The company has a fifty day moving average price of $30.00 and a 200-day moving average price of $28.05. The stock has a market capitalization of $4.07 billion and a price-to-earnings ratio of -25.57. Heartflow, Inc. has a 1-year low of $20.13 and a 1-year high of $47.95.

Heartflow (NASDAQ:HTFL - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.15. The business had revenue of $64.08 million during the quarter. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.The company's quarterly revenue was up 47.7% compared to the same quarter last year. Equities research analysts forecast that Heartflow, Inc. will post -0.82 EPS for the current fiscal year.

Institutional Investors Weigh In On Heartflow

A number of institutional investors have recently modified their holdings of HTFL. Alyeska Investment Group L.P. grew its stake in shares of Heartflow by 55.6% in the second quarter. Alyeska Investment Group L.P. now owns 350,000 shares of the company's stock valued at $10,269,000 after acquiring an additional 125,000 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Heartflow by 3.6% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,465,650 shares of the company's stock worth $43,002,000 after purchasing an additional 50,822 shares in the last quarter. XXEC Inc. bought a new stake in Heartflow in the 2nd quarter valued at about $18,364,000. Corient Private Wealth LP acquired a new position in shares of Heartflow during the 2nd quarter worth approximately $1,457,000. Finally, Bamco Inc. NY acquired a new position in shares of Heartflow during the 2nd quarter worth approximately $94,625,000.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Weiss Ratings raised Heartflow from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, August 7th. Wells Fargo & Company raised their price target on Heartflow from $37.00 to $39.00 and gave the company an "overweight" rating in a report on Friday, August 14th. Stifel Nicolaus lifted their price objective on shares of Heartflow from $40.00 to $45.00 and gave the stock a "buy" rating in a research report on Friday, August 14th. William Blair assumed coverage on shares of Heartflow in a research report on Monday, May 4th. They issued an "outperform" rating on the stock. Finally, Canaccord Genuity Group raised their target price on shares of Heartflow from $37.00 to $45.00 and gave the stock a "buy" rating in a research note on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $43.43.

Heartflow Company Profile

HeartFlow, Inc NASDAQ: HTFL is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source